Skip to main content
OpenTrials
Completed

NCT Number: NCT04667195

Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis

Acute pyelonephritis is an acute infection. Today the diagnosis is made primarily on the basis of unspecific clinical symptoms with flank tenderness combined with as a key clue. This study will investigate which clinical and paraclinical characteristics available within 4 hours of hospital stay, that describes the patients admitted in the emergency department with acute pyelonephritis the best.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Acute pyelonephritis (APN) is a severe acute infection in the upper urinary tract, which quite frequently is seen in the emergency department (ED). In our study, we define APN as a urinary tract infection with extension above the bladder, implicated by systemic affection in a suspected urinary tract infection (ie, fever, chills, malaise and/or lethargy beyond normal, signs of sepsis). Most often, an infection of the bladder ascends to the kidneys, causing APN. Symptoms and clinical affection range from mild to severe, but it is always important to recognize and treat APN fast in order to prevent progression to sepsis, renal failure and ultimately death.

The diagnosis APN is primarily made clinically based on symptoms and supported by elevated biomarkers such as C-reactive protein (CRP) and leucocytes, and positive urinary test strips. The diagnostic process can be challenging as there is often weak and atypical symptoms.

The classic symptoms indicating APN is flank tenderness, fever and nausea/vomiting. Typical symptoms of cystitis (dysuria, pollakisuria, suprapubic pain, hematuria) are possible but often absent. Especially elderly can present with more generalized signs of infection with nothing clearly indicating localization to the urinary tract. A positive urine culture verifies the diagnosis, but it is only available after a minimum of 24 hours.

In this study, we seek to identify and quantify the patient characteristics available within 4 hours of hospital stay in patients with APN. The objectives are:

  • To identify clinical and paraclinical relevant information available within 4 hours of admission that are associated with APN patients
  • To investigate the association between adverse events and clinical and paraclinical relevant information in patients with APN.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Suspicion of APN assessed by the receiving physician.

Exclusion criteria

  • If the attending physician considers that participation will delay a life-saving treatment or patient needs direct transfer to the intensive care unit.
  • Admission within the last 14 days
  • Verified COVID-19 disease within 14 days before admission
  • Pregnant women
  • Severe immunodeficiencies: Primary immunodeficiencies and secondary immunodeficiencies (HIV positive CD4 <200, Patients receiving immunosuppressive treatment (ATC L04A), Corticosteroid treatment (>20 mg/day prednisone or equivalent for >14 days within the last 30 days), Chemotherapy within 30 days)

Treatment and study plan

Clinical Assessment

Other

Within 4 hours of admission to the emergency department, clinical assessment will include:

  • Demographics,
  • comorbidity,
  • symptoms,
  • objective findings,
  • triage at admission,
  • blood test results,
  • urine test results

Primary outcomes

  1. Verified and non verified APN

    Time frame: 2 months after patient discharge

    The decision of whether patients admitted with suspicion of APN actually has a final diagnosis of APN is based on a combination of all findings during admission. The verification of diagnosis requires human handling, interpretation and judgment. Therefore, in this study, an expert panel will define the reference standard for the diagnosis APN. The expert panel consists of two independent consultants from the emergency department with significant experience in emergency medicine and acute infections. They will individually determine whether or not the patient admitted suspected with APN actually had this diagnosis. The final diagnosis will be based on all available relevant information from the patient medical record including MRI of the kidneys. A standardized template will be used. Disagreement will be discussed until a consensus is reached.

Secondary outcomes

  1. Intensive care treatment

    Time frame: within 60 days from admission to the emergency department

    Transfer to the intensive care unit will be recorded during the current hospitalization as a binary variable (transferred/not-transferred)

  2. Length of hospital stay

    Time frame: within 60 days from current admission to the emergency department

    days spent in hospital during current admission

  3. 30-days mortality

    Time frame: within 30 days from arrival day

    binary

  4. Readmission

    Time frame: 30 days from day of discharge

    If a subject is admitted over a 30 day period after the current hospitalization discharge measured as a binary outcome

  5. In-hospital mortality

    Time frame: within 60 days from current admission to the emergency department

    binary

Other outcomes

  1. 90-days mortality

    Time frame: within 90 days from day of admission

    binary

  2. Level of infection markers

    Time frame: within 4 hours from admission

    Concentration of serum procalcitonin, CRP and suPAR

  3. Urological intervention

    Time frame: within 60 days from current admission to the emergency department

    Binary

  4. Bacteriuria

    Time frame: within 4 hours from admission

    Binary outcome defined by microbiologist on urine culture analysis

Sponsors and collaborators

Lead sponsor

University of Southern Denmark

Other

Registry information

Official study title

Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis in the Emergency Department: A Cross-sectional Study

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 14, 2020
Registry last updated
Sep 14, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.